CLAIMS:

1. Use of at least one peptide, suitable for eliciting an immune response, for the manufacture of a medicament for the treatment of cancer by simultaneous or sequential administration with an anti-metabolite chemotherapeutic agent, wherein the or each peptide corresponds to a fragment of a wild-type RAS protein but has one amino acid substitution thereof, and wherein the or each peptide comprises a region of at least 8 amino acids which includes position 12 or 13 of the RAS protein, and wherein the amino acid substitution of the or each peptide is at said position 12 or 13, respectively, and is selected from a G13A, G13C, G13D, G13R, G13S, G13V, G12A, G12C, G12D, G12R, G12S or a G12V substitution.

2. Use of the at least one peptide according to claim 1, wherein the at least one peptide comprises two or more peptides, each peptide having a different amino acid substitution.

3. Use of the at least one peptide according to any preceding claim, wherein the at least one peptide comprises:

a peptide having a G13D substitution
a peptide having a G12A substitution
a peptide having a G12C substitution
a peptide having a G12D substitution
a peptide having a G12R substitution
a peptide having a G12S substitution, and
a peptide having a G12V substitution.

4. Use of the at least one peptide according to claim 1 or 2, wherein the at least one peptide comprises:

a peptide having a G13D substitution
a peptide having a G13C substitution
a peptide having a G12A substitution
a peptide having a G12C substitution
a peptide having a G12D substitution
a peptide having a G12R substitution
a peptide having a G12S substitution, and
a peptide having a G12V substitution.

5. Use of the at least one peptide according to any preceding claim, wherein the anti-metabolite chemotherapeutic agent is a pyrimidine analogue or a pharmaceutically acceptable salt thereof.

6. Use of the at least one peptide according to any preceding claim, wherein the at least one peptide comprises a peptide consisting of the sequence represented by SEQ ID NO: 13, a peptide consisting of the sequence represented by SEQ ID NO: 14, a peptide consisting of the sequence represented by SEQ ID NO: 15, a peptide consisting of the sequence represented by SEQ ID NO: 16, a peptide consisting of the sequence represented by SEQ ID NO: 17, a peptide consisting of the sequence represented by SEQ ID NO: 18, a peptide consisting of the sequence represented by SEQ ID NO: 19 and a peptide consisting of the sequence represented by SEQ ID NO: 20.

7. Use of the at least one peptide according to any preceding claim, wherein the cancer comprises cells which express a mutated RAS protein.

8. Use of the at least one peptide according to any preceding claim, wherein the anti-metabolite chemotherapeutic agent is first to be administered at least three weeks after the first dose of the at least one peptide.

9. Use of the at least one peptide according to claim 7, wherein the cancer is resected pancreatic cancer and the anti-metabolite chemotherapeutic agent is first to be administered 12 weeks or fewer after surgical resection of the pancreatic cancer.

10. Use of the at least one peptide according to any preceding claim, wherein the anti-metabolite chemotherapeutic agent is to be administered within 24 hours of the at least one peptide.

11. Use of the at least one peptide according to claim 10, wherein the anti-metabolite chemotherapeutic agent is to be administered after the at least one peptide has been administered.

12. Use of the at least one peptide according to any preceding claim, wherein the at least one peptide is to be administered at a dosage of 0.01-10mg.

13. Use of the at least one peptide according to any preceding claim, wherein the anti-metabolite chemotherapeutic agent is to be administered at a dosage of 100-10,000 mg/m^2.

14. Use of the at least one peptide according to any preceding claim, wherein the at least one peptide and the anti-metabolite chemotherapeutic agent are to be administered simultaneously or sequentially at at least two instances, wherein each instance of administration is separated by at least one week.

15. Use of at least one T-cell specific for the at least one peptide according to any of the preceding claims, or a T-cell preparation comprising T-cells specific for the at least one peptide as defined in any of the preceding claims when presented on an MHC molecule, for the manufacture of a medicament for the treatment of cancer by simultaneous or sequential administration with an anti-metabolite chemotherapeutic agent.

16. A pharmaceutical composition comprising at least one peptide as defined in any of claims 1-14, or at least one T-cell or a T-cell preparation as defined in claim 15, for the manufacture of a medicament for the treatment of cancer by combined or sequential administration with an anti-metabolite chemotherapeutic agent.